Trial Profile
Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms AERN
- 12 Sep 2023 Planned primary completion date changed from 1 May 2023 to 1 Oct 2023.
- 05 Aug 2022 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 05 Aug 2022 Planned primary completion date changed from 1 May 2022 to 1 May 2023.